Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab versus docetaxel in previously treated non-small cell lung cancer
2018-000245-39Phase 3Completed
- Sponsor
- BeiGene
- Start
- May 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Tislelizumab with Docetaxel (2 arms). Primary endpoint: Overall survival. Started May 2018; status: completed.
02
Drugs
tislelizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-000245-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000245-39.